SAGE PRO

Home / Research / Deepak Nitrite Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Deepak Nitrite Limited — Q2 FY27 Results Analysis

Quarterly sales expanded 61%

Published · Quarter Q2 FY27 · DEEPAKNTR

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Consolidated revenue

Q2 FY26₹1,922 crore
Q2 FY27₹3,091 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 2

Consolidated EBITDA

Q2 FY26₹224 crore
Q2 FY27₹643 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 3

Consolidated PBT

Q2 FY26₹163 crore
Q2 FY27₹543 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 4

Consolidated PAT

Q2 FY26₹119 crore
Q2 FY27₹398 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Quarterly sales expanded 61%

Revenue is consolidated, not segment-only

Watch: Track profitability

RESEARCH INSIGHT

EBITDA rose much faster than sales

Phenolics profitability drove operating leverage

Watch: Check durability

RESEARCH INSIGHT

PBT expanded on stronger operations

Funding and taxes still matter

Watch: Reconcile profit to cash

RESEARCH INSIGHT

PAT increased from a low base

Growth is not cash conversion

Watch: Monitor operating cash

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Deepak Nitrite Limited (DEEPAKNTR) — Q2 and H1 FY2027, quarter ended 30 September 2026. Consolidated issuer presentation and management conference-call evidence.

Decision: WATCH for cash-backed durability of the phenolics recovery and improved Advanced Intermediates utilisation. The company reported its highest-ever consolidated quarterly revenue and EBITDA. Revenue was ₹3,091 crore, up 61% year on year from ₹1,922 crore; EBITDA ₹643 crore, up 187% from ₹224 crore; PBT ₹543 crore versus ₹163 crore; and PAT ₹398 crore versus ₹119 crore. The Q2 EBITDA margin reached 20.8%, versus 11.6% a year earlier. These are the issuer's presented consolidated figures, not a forecast. [S2]

Consolidated metric, ₹ croreQ2 FY26Q1 FY27Q2 FY27H1 FY26H1 FY27
Revenue1,9222,5923,0913,8365,682
EBITDA2245546434381,197
PBT1634685433181,010
PAT119345398231743

The half-year comparison is just as important: H1 revenue increased 48% to ₹5,682 crore, EBITDA increased 173% to ₹1,197 crore, and PAT increased 221% to ₹743 crore. The presentation gives an H1 EBITDA margin of 21.1% versus 11.3% a year earlier. The company is growing from a particularly weak comparative operating-profit base, so extrapolating the reported percentage gains into a steady-state forecast would be misleading. [S2]

Six investor takeaways

  • Q2 consolidated revenue increased to ₹3,091 crore from ₹1,922 crore; sequential revenue rose from ₹2,592 crore. [S2]
  • Q2 EBITDA reached ₹643 crore against ₹224 crore a year earlier, supported predominantly by the Phenolics business. [S1][S2]
  • Q2 PAT rose to ₹398 crore from ₹119 crore; this does not independently establish operating cash-flow conversion. [S2]
  • Phenolics quarterly revenue was ₹2,291 crore versus ₹1,333 crore, while segment EBIT reached ₹515 crore versus ₹145 crore. [S2]
  • Advanced Intermediates quarterly revenue increased to ₹811 crore versus ₹588 crore, but EBIT increased only to ₹49 crore from ₹23 crore; the business remains a utilisation and pricing watchpoint. [S1][S2]
  • Management reported consolidated net debt of ₹1,657 crore at September 2026, versus ₹1,676 crore in June, and a cash conversion cycle of 53 days versus 57 days. [S1]

Valuation threshold: The accepted filings do not establish a current share price, diluted share count or comparable enterprise value. A price target would be invented. Investment conviction should instead depend on sustained phenolics spreads and volumes, AI capacity utilisation, post-capex free cash flow and the return earned on the group's new integrated chemical investments.

Chapter 1 — Investment decision and what must be underwritten

Deepak Nitrite's Q2 recovery is a powerful example of the difference between revenue expansion and operating leverage. Revenue rose 61%, but EBITDA increased 187% on the company's consolidated presentation. This is encouraging, but the most important question is whether the conditions behind that margin expansion will persist as international chemical supply chains normalise. Management attributed phenolics performance to healthy plant throughput, sourcing agility and supply-chain disruptions that favoured reliable domestic producers. A structural competitive advantage may be emerging, but a temporary disruption can also generate unusually attractive spreads. [S1][S2]

The investment case has two different engines. Phenolics is presently producing the strongest earnings momentum, while Advanced Intermediates is being repositioned toward volume-led recovery and new capacity. These divisions should not be assigned identical margin assumptions. The management call described uneven end-market demand and import-led inventory pressure in AI, despite the stronger consolidated headline. [S1]

Decision tests

  • Require Phenolics segment EBIT to remain healthy after temporary global sourcing disruptions ease. [S1]
  • Track AI plant utilisation and EBIT alongside its reported 38% revenue growth. [S1][S2]
  • Monitor consolidated cash conversion rather than assuming EBITDA growth equals distributable cash. [S1]
  • Review net debt and project commissioning together; the new asset base must ultimately generate incremental returns. [S1]
  • Distinguish Q2's realised ₹643 crore EBITDA from any prospective run-rate suggested by management. [S2]

Chapter 2 — Consolidated financials, profitability and earnings quality

The issuer's Q2 financial table reports consolidated revenue ₹3,091 crore, EBITDA ₹643 crore, PBT ₹543 crore and PAT ₹398 crore. Compared with Q1 FY27, these were respectively ₹2,592 crore, ₹554 crore, ₹468 crore and ₹345 crore. Q2 revenue growth was therefore approximately 19% sequentially, EBITDA approximately 16%, and PAT approximately 15%, consistent with the company's rounded published growth percentages. The comparison shows that sequential EBITDA did not outgrow sales even though year-on-year operating leverage was exceptional. [S2]

The presentation shows Q2 FY26 revenue ₹1,922 crore, EBITDA ₹224 crore, PBT ₹163 crore and PAT ₹119 crore. On those values, the EBITDA margin improved from approximately 11.7% to 20.8%; the company reports 11.6% for the prior period, a small difference arising from rounded presentation figures. It would be inaccurate to imply the same improvement occurred every quarter. Q1 FY27's EBITDA margin from rounded figures was approximately 21.4%, slightly higher than Q2. [S2]

The H1 numbers are revenue ₹5,682 crore, EBITDA ₹1,197 crore, PBT ₹1,010 crore and PAT ₹743 crore. The corresponding H1 FY26 values were ₹3,836 crore, ₹438 crore, ₹318 crore and ₹231 crore. The H1 margin comparison—21.1% versus 11.3%—shows that the recovery spans more than a single quarter, although it still coincides with a volatile global feedstock environment. [S2]

The selected presentation provides a headline consolidated PBT and PAT table, but the excerpts used here do not support a full exceptional-item and tax bridge. Consequently these values are reported as the company's published consolidated presentation figures, not reclassified as adjusted or normalised profit. Neither the EBITDA-to-PAT spread nor a margin ratio can substitute for a statutory cash-flow statement. A responsible investor should request actual operating cash flow and cash taxes when judging earnings quality.

Financial interpretation

  • The year-on-year EBITDA increase of ₹419 crore is large relative to the ₹1,169 crore revenue increase, implying strong incremental operating leverage in this period. [S2]
  • Sequential EBITDA rose ₹89 crore on ₹499 crore higher revenue; this is a more restrained incremental picture than the annual comparison. [S2]
  • H1 PAT of ₹743 crore is more than three times H1 FY26's ₹231 crore, but the comparison begins from a depressed base. [S2]
  • Margin sustainability must be tested by segment and by cash receipts, not by consolidated headline percentages alone.

Chapter 3 — Phenolics and Advanced Intermediates: very different economics

Phenolics was the decisive contributor to quarterly operating improvement. Its revenue increased to ₹2,291 crore from ₹1,333 crore in Q2 FY26; its EBIT rose to ₹515 crore from ₹145 crore. The segment's implied EBIT-to-revenue ratio on the rounded presentation figures is about 22.5%, compared with 10.9% a year earlier. This is a segment EBIT calculation, not consolidated EBITDA margin. [S2]

Management said the phenolics chain maintained high throughput, with several assets operating at or above rated capacity. The company described import disruptions and customer preference for assured domestic supply as factors improving competitive positioning. This explains why a high utilisation level and a favourable market spread can reinforce one another. The risk is symmetrical: when global imports normalise or feedstock costs change, pricing and contribution margins may not remain at this unusually strong level. [S1]

Advanced Intermediates reported Q2 revenue ₹811 crore against ₹588 crore a year earlier, approximately 38% growth, while EBIT was ₹49 crore versus ₹23 crore. Its derived EBIT margin is about 6.0% against 3.9% a year earlier. Although profitability improved, the division is much less profitable than Phenolics on this measure. The issuer presentation also shows AI Q1 revenue around ₹804 crore and EBIT ₹67 crore, so Q2 AI EBIT declined sequentially despite broadly stable revenue. [S1][S2]

The call explained that earlier strong domestic demand prompted customers to procure imported material at elevated raw-material prices; some imports arrived in July and reduced domestic plant utilisation. Management is emphasising integration from ammonia to amines and from propylene to polycarbonate, along with new product commercialisation. These investments may strengthen cost competitiveness, but the near-term economics depend on volumes and product pricing. [S1]

The Q2 revenue mix shown in the presentation was approximately 88% domestic and 12% export. That highlights exposure to domestic industrial demand and import substitution, but it should not be mistaken for an immunity to global feedstock or finished-product pricing. [S2]

Segment watchpoints

  • Phenolics generated ₹515 crore Q2 EBIT versus AI's ₹49 crore; the group is heavily exposed to the stronger division's current economics. [S2]
  • AI EBIT declined from the presentation's ₹67 crore Q1 level to ₹49 crore Q2 despite similar revenue. [S2]
  • Management's import and utilisation explanation needs validation through future production volumes and EBIT. [S1]
  • Treat segment EBIT, consolidated EBITDA and PAT as different measures with different cost allocations.

Chapter 4 — Capacity, project execution and the analyst Q&A

The earnings call described the expansion programme as moving from construction toward commissioning and commercialisation in selected product lines. Management expects new assets to contribute incremental revenue and efficiencies as utilisation stabilises. This is a credible operational roadmap, but the timing of customer qualifications, ramp-up losses and final returns cannot be inferred from an announcement of mechanical completion. [S1]

The integrated polycarbonate initiative at Dahej remains an important strategic project. Management described progress on the site and the dismantling and relocation activities in Germany, alongside customer qualification work for polycarbonate compounds. This is a longer-cycle advanced-materials opportunity; no current-quarter revenue should be attributed to future capacity without evidence of actual sales. [S1]

The call's analyst questions tested the AI margin recovery rather than merely celebrating the group record. One analyst referenced a completed approximately ₹300 crore fluorination capex and asked how that asset and nitration benefits would change profitability. Management expected Q3 AI EBIT percentage to lie between Q1 and Q2, closer to Q1, while newly added assets should contribute over time. This is a forward-looking operating expectation, not a booked result or an independently verified capex cash outflow. [S1]

Management also discussed new product and downstream integration opportunities. Investors should distinguish three stages: technical completion, qualified customer demand and commercially profitable throughput. Only the third stage establishes that the investment is earning an economic return. A project that is technically ready can still require working capital, depreciation and financing before revenue reaches the intended scale.

Execution checklist

  • Confirm actual commercial sales and segment profit from commissioned fluorination and nitration investments. [S1]
  • Track Dahej polycarbonate milestones separately from existing phenolics earnings. [S1]
  • Compare management's Q3 AI margin expectation with the next reported EBIT/revenue ratio. [S1]
  • Watch customer qualification timelines and working-capital needs during ramp-up. [S1]

Chapter 5 — Net debt, working capital, capex and payback

Management reported consolidated net worth of ₹6,521 crore at September 2026. Consolidated net debt was ₹1,657 crore, versus ₹1,676 crore at the preceding quarter-end. The net debt-to-equity ratio improved from 0.27x to 0.25x. These are management's stated consolidated measures and should not be combined with any standalone debt number. [S1]

The net cash conversion cycle shortened to 53 days from 57 days in Q1. Management credited inventory efficiency and receivables discipline. A four-day improvement is operationally encouraging, but without the actual quarterly cash-flow statement it is not possible to convert that change into a verified cash release or free cash flow. The improvement also must be tested against the inventory demands of newly commissioned capacity. [S1]

The expansion programme is capital intensive. The approximately ₹300 crore fluorination capex mentioned in analyst Q&A is an individual project reference, not a full consolidated cash capex figure. The selected evidence does not provide a reliable complete group cash capex bridge, depreciation schedule or project-level invested capital. Therefore this report does not claim a fabricated project payback period. [S1]

The capital allocation challenge is to sustain the profitable phenolics base while funding AI and downstream products without allowing leverage to rise faster than operating cash generation. Management said financing arrangements for its investments were in place and that it was monitoring project expenditure, funding requirements and cash flow. That provides a funding framework but not a guaranteed cash return. [S1]

Cash and leverage tests

  • Track reported net debt against the September reference of ₹1,657 crore, with consistent consolidation and cash definitions. [S1]
  • Compare future net cash conversion cycle with 53 days, not with an assumed industry benchmark. [S1]
  • Require group operating cash flow, cash capex and interest payments before inferring free cash flow.
  • Assess payback on new assets only after commercial utilisation and segment earnings become observable.
  • Separate a ₹300 crore project reference from total quarterly capital expenditure. [S1]

Chapter 6 — Conditional bull, base and bear cases

Bull case — phenolics strength persists and AI catches up. Phenolics continues to benefit from high utilisation and reliable supply, while AI plants regain utilisation and newly commissioned assets lift segment EBIT. The group converts EBITDA into cash, reduces its working-capital cycle further and funds growth without material leverage deterioration. This case would be confirmed by durable segment EBIT, operating cash flow and new-project revenue rather than management commentary alone. [S1][S2]

Base case — record earnings normalise but capacity contributes. Phenolics spreads moderate from the unusually favourable Q2 environment while AI volume growth and project ramp-up gradually offset the decline. Revenue expands, but consolidated margins fluctuate around feedstock cycles and new-facility operating costs. Debt remains manageable, though capital investment limits near-term free cash flow. This is a scenario, not a numerical forecast.

Bear case — temporary spreads reverse before new assets mature. Import competition and lower phenolics pricing compress segment EBIT, AI remains exposed to underutilisation, and newly commissioned capacity adds depreciation and working-capital needs without adequate contribution. The strong Q2 growth rates prove cyclical rather than durable. Financing costs and slower cash conversion would then constrain returns even if headline revenue stays high.

Falsifiers

  • Phenolics EBIT margin falls sharply from the roughly 22.5% derived Q2 level without offsetting AI recovery. [S2]
  • AI EBIT remains below its Q1 ₹67 crore reference despite new capacity. [S2]
  • Net debt rises materially above ₹1,657 crore without identifiable cash-generating assets. [S1]
  • The cash conversion cycle reverses its improvement from 57 to 53 days. [S1]
  • New-product commissioning is repeatedly deferred or fails to translate into commercial sales. [S1]

These cases deliberately omit invented revenue forecasts, price targets and terminal multiples.

Chapter 7 — Quarterly investor action plan

Action: WATCH; demand evidence that the record quarter becomes sustainable cash-generating performance. Deepak Nitrite has delivered impressive consolidated profit recovery. Yet its current value depends on two tests: whether phenolics profitability survives a more normal global market, and whether Advanced Intermediates earns acceptable returns on the expansion programme.

ItemLatest supported referenceNext-quarter question
Consolidated Q2 revenue₹3,091 croreDoes growth remain broad-based?
Consolidated Q2 EBITDA₹643 croreDoes margin remain resilient?
Consolidated Q2 PAT₹398 croreHow does PAT convert to cash?
H1 revenue / EBITDA₹5,682 crore / ₹1,197 croreIs operating leverage sustainable?
Phenolics Q2 revenue / EBIT₹2,291 crore / ₹515 croreAre spreads and throughput holding?
AI Q2 revenue / EBIT₹811 crore / ₹49 croreDoes utilisation recover?
Consolidated net debt₹1,657 croreAre new projects self-funding?
Net debt-to-equity0.25xIs leverage still controlled?
Net cash conversion cycle53 daysDoes inventory discipline continue?
Fluorination projectAnalyst-cited ~₹300 crore capexIs commercial EBIT contribution visible?
Polycarbonate initiativeDahej and German relocation progressAre qualification and commissioning milestones met?

Questions for the next results call

  • What proportion of the Phenolics Q2 EBIT uplift reflects volumes, raw-material costs, product spreads and temporary supply-chain disruption? [S1][S2]
  • Can AI recover Q1's ₹67 crore EBIT as management anticipates stronger utilisation? [S1][S2]
  • How much of the new project capacity is producing commercial shipments versus awaiting qualifications? [S1]
  • What are consolidated operating cash flow, cash capex and net debt on the same reporting basis?
  • Are the 53-day conversion cycle and 0.25x debt-to-equity ratio sustainable during commissioning? [S1]
  • What project-level returns are becoming visible from fluorination, nitration and downstream integration? [S1]

Evidence limitations specific to this decision: The accepted presentation and call establish consolidated operating results, segment revenue and EBIT, net debt and conversion-cycle commentary. They do not establish a full project-by-project return-on-capital bridge, a complete cash capex and free-cash-flow statement, current market valuation or a statutory-versus-adjusted profit reconciliation sufficient for a precise target price. These gaps are left unfilled rather than replaced by assumptions.

Original issuer/exchange filings

All rupee amounts are in crore. Consolidated EBITDA and PAT, segment EBIT, management commentary and derived margins are separately identified.

Additional company evidence

CHART 5

H1 consolidated revenue

H1 FY26₹3,836 crore
H1 FY27₹5,682 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 6

H1 consolidated EBITDA

H1 FY26₹438 crore
H1 FY27₹1,197 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 7

H1 consolidated PBT

H1 FY26₹318 crore
H1 FY27₹1,010 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

CHART 8

H1 consolidated PAT

H1 FY26₹231 crore
H1 FY27₹743 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.